Latest reporting
Responding to the Emerging Threat of Xylazine
On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.
Arizona Has $1.2 Billion to Fix Its Addiction Crisis. Here Is What Is Happening to the Money.
Arizona has $1.215 billion in opioid settlement funds over 15+ years. How those dollars get allocated — and what the SAMHSA block grant consolidation threatens — matters for every person seeking treatment in the state.
A 24% Drop in Overdose Deaths Is Real. So Is the Racial Gap That Didn't Shrink.
The age-adjusted overdose death rate fell 24.4% from 2023 to 2024 — the largest single-year drop on record. But stimulant-only deaths rose, and American Indian/Alaska Native people face a rate 2x the national average.
Through eight lenses
Science
Opioids bind to μ, δ, and κ receptors in the central and peripheral nervous system. Agonists (morphine, heroin, fentanyl) produce analgesia, euphoria, and respiratory depression; partial agonists (buprenorphine) and antagonists (naloxone, naltrexone) occupy receptors differently. Fentanyl's potency (~50–100× morphine) reflects receptor affinity, not a different mechanism — which is why overdose reversal still works, just often requiring higher or repeated naloxone doses.
Biology
Acute effects: respiratory depression (the killer), miosis, GI slowdown, analgesia. Chronic use downregulates endogenous opioid production, which is the neurobiology behind withdrawal — real, measurable, not "in someone's head." Long-term health impacts include endocrine suppression, constipation, cardiovascular stress, and (with injection) endocarditis and soft-tissue infections. Fentanyl's pharmacokinetics (rapid onset, short half-life in plasma but redistribution into tissue) explain its overdose profile.
Psychology
Opioid use disorder has the highest bio-genetic contribution of any SUD in twin studies (~50–60% heritability). The "warm blanket" subjective experience — which people in active use describe consistently — reflects μ-receptor activation in regions governing social pain. That's why opioids map so cleanly onto trauma, loneliness, and chronic pain.
Policy
Schedule II (except buprenorphine at III, heroin at I). DEA quota system governs legitimate supply. The 2023 X-Waiver elimination removed the barrier to buprenorphine prescribing — any provider with a Schedule III DEA number can now prescribe. [Telehealth prescribing is extended through 2026](/newsroom/dea-extends-telemedicine-buprenorphine-2026) with permanent 6-month flexibility for buprenorphine.
Trends
CDC provisional data shows ~72,000 overdose deaths in the 12 months ending October 2025, a 17% decline from the 2023 peak of ~107,000. Synthetic opioids (fentanyl + analogs) remain in 69–75% of these deaths. Emerging: nitazenes (more potent than fentanyl, naloxone-reversible but may require higher doses) and xylazine (not an opioid, but in the supply — see [SP-15](/newsroom/xylazine-what-it-is-why-it-matters)).
Treatment
[MAT](/newsroom/mat-explained-2026) is the evidence-based standard: buprenorphine, methadone, and extended-release naltrexone all reduce mortality by ~50% vs. non-medication treatment in meta-analyses. Counseling helps but is not required to start MAT. Residential programs, IOP, peer recovery coaching, and 12-step all have roles, but without MAT the evidence for OUD treatment alone is weak.
Harm Reduction
Naloxone saves lives and is now available OTC (Narcan) in most states. Fentanyl test strips, safer-use education, Good Samaritan protections, syringe service programs, and (in some jurisdictions) overdose prevention centers. Harm reduction is not antithetical to recovery — SAMHSA's 2022 harm reduction pillar makes this explicit.